Barinthus Biotherapeutics plc (BRNS)
| Previous close | 2.2300 |
| Open | 2.2144 |
| Bid | 0.0000 x 0 |
| Ask | 2.4500 x 100 |
| Day's range | 2.2144 - 2.4499 |
| 52-week range | 1.6400 - 5.1000 |
| Volume | |
| Avg. volume | 24,439 |
| Market cap | 88.351M |
| Beta (5Y monthly) | -0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.40 |
Simply Wall St.Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
Key Insights Barinthus Biotherapeutics will host its Annual General Meeting on 10th of May Salary of US$610.0k is part...
GlobeNewswireBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseasesOXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today an
- GlobeNewswire
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the groups receiving the highest ChAdOx dose.Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in compari
